Literature DB >> 14622694

Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review.

Ewan McNicol1, Nathalie Horowicz-Mehler, Ruth A Fisk, Kyle Bennett, Maria Gialeli-Goudas, Priscilla W Chew, Joseph Lau, Daniel Carr.   

Abstract

Side effects can limit opioid dosage and reduce quality of life. The purpose of this systematic review was to assess the management of opioid side effects in the context of cancer pain management or, in the event that no evidence was available for cancer pain, for chronic noncancer pain. The side effects studied were constipation, pruritus, nausea and vomiting, myoclonus, sedation, respiratory depression, and delirium. Opioid rotation to manage side effects was also studied. For each side effect, we searched MEDLINE and the Cochrane Controlled Trials Register and identified 657 possible titles for inclusion. Of these, 67 studies met inclusion criteria for analysis. The lack of well-designed, randomized controlled trials and the heterogeneity of populations and study designs made the drawing of firm conclusions difficult and precluded performance of meta-analysis. The type, strength, and consistency of evidence for available interventions to manage opioid side effects vary from strong (eg, on the use of naloxone to reverse respiratory depression or constipation) to weak (eg, changing from the oral to epidural route of morphine administration to manage sedation). Well-designed trials in the specified populations are required to furnish clinicians with secure evidence on managing opioid side effects successfully.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622694     DOI: 10.1016/s1526-5900(03)00556-x

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  103 in total

Review 1.  Management of opioid-induced bowel dysfunction in cancer patients.

Authors:  Antonio Cesar Tamayo; Paola Andrea Diaz-Zuluaga
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

2.  17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

Authors:  Yan Zhang; Dwight A Williams; Saheem A Zaidi; Yunyun Yuan; Amanda Braithwaite; Edward J Bilsky; William L Dewey; Hamid I Akbarali; John M Streicher; Dana E Selley
Journal:  ACS Chem Neurosci       Date:  2016-01-08       Impact factor: 4.418

3.  Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.

Authors:  Amanda Ford; Annie Castonguay; Martin Cottet; Joshua W Little; Zhoumou Chen; Ashley M Symons-Liguori; Timothy Doyle; Terrance M Egan; Todd W Vanderah; Yves De Koninck; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

4.  Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain.

Authors:  Patrice Villars; Marylin Dodd; Claudia West; Theresa Koetters; Steven M Paul; Karen Schumacher; Debu Tripathy; Peter Koo; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2007-01       Impact factor: 3.612

Review 5.  Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.

Authors:  Daniel P Alford; Peggy Compton; Jeffrey H Samet
Journal:  Ann Intern Med       Date:  2006-01-17       Impact factor: 25.391

6.  Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain.

Authors:  Chun-Lei Zhang; Ting-Jie Zhang; Yu-Na Guo; Li-Qiang Yang; Ming-Wei He; Jing-Zhe Shi; Jia-Xiang Ni
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

7.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

8.  Prevalence of opioid dispensings and concurrent gastrointestinal medications in Quebec.

Authors:  R E Williams; N Bosnic; C T Sweeney; A W Duncan; K B Levine; M Brogan; S F Cook
Journal:  Pain Res Manag       Date:  2008 Sep-Oct       Impact factor: 3.037

Review 9.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 10.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.